| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Ginsenoside Rg6 targets the NF-kappaB signaling pathway. It inhibits TNF-alpha-induced NF-kappaB transcriptional activity. The compound also induces apoptosis through mitochondrial dysfunction, increasing Bax expression and decreasing Bcl-2 expression. It inhibits phosphorylation of CDK2 at Thr160 by upregulating p21 levels.
|
|---|---|
| ln Vitro |
Ginsenoside Rg6 suppresses TNF-α-induced NF-κB transcriptional activity in SK-Hep1 cells with an IC50 of 25.12±1.04 μM, comparable with the data in HepG2 cells [1]. Ginsenoside Rg6 showed obvious anti-proliferation and apoptosis-inducing actions when administered to JK cells in vitro. Ginsenoside Rg6 prevents S arrest in the cell cycle. The CCK-8 method indicated that with the administration of ginsenoside Rg6, multiple groups at different concentrations can significantly limit the proliferation of JK cells in human lymphoma, and it has a clear dose dependence. According to IC50 estimate, the median inhibitory concentration of ginsenoside Rg6 is 83.08 μM[2].
In vitro, Ginsenoside Rg6 inhibits TNF-alpha-induced NF-kappaB transcriptional activity with an IC₅0 of 25.12-29.34 microM in SK-Hep1 and HepG2 cells. It inhibits the proliferation and induces apoptosis of human lymphoma JK cells through mitochondrial dysfunction. The compound increases Bax expression and decreases Bcl-2 expression. |
| ln Vivo |
In vivo activity data for Ginsenoside Rg6 are not extensively documented. As a natural product with anti-inflammatory and anticancer properties, the compound is expected to show efficacy in inflammatory and tumor models. Further in vivo studies would be needed to characterize its pharmacokinetic and efficacy profile. The compound is used in research for neuroprotection and metabolic regulation.
|
| Enzyme Assay |
The in vitro NF-kappaB transcriptional activity assay uses luciferase reporter gene constructs in SK-Hep1 or HepG2 cells. Cells are transfected with NF-kappaB-luciferase reporter plasmids and treated with TNF-alpha to induce NF-kappaB activation. Ginsenoside Rg6 is added at various concentrations, and luciferase activity is measured. IC₅0 values are calculated from dose-response curves.
|
| Cell Assay |
For in vitro cell-based assays, lymphoma JK cells or HepG2 cells are cultured and treated with Ginsenoside Rg6 at various concentrations. Cell proliferation is measured using MTT, CellTiter-Glo, or direct cell counting. Apoptosis is assessed by measuring caspase activity, Annexin V staining, or Bax/Bcl-2 expression by Western blot. NF-kappaB activity is measured using luciferase reporter assays. Experiments are typically performed in triplicate.
|
| Animal Protocol |
In vivo animal studies for Ginsenoside Rg6 would typically involve mouse models of inflammation (such as LPS-induced inflammation) or xenograft tumor models. The compound is administered orally or intraperitoneally at various doses. Inflammatory markers (such as IL-12 p40) are measured in serum or tissue samples. Tumor volume is measured in xenograft models. Efficacy is evaluated by reduction in inflammatory parameters or tumor growth inhibition.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Ginsenoside Rg6 are not extensively documented. The compound has molecular formula C42H₇0O12 and molecular weight 766.0. It is soluble in DMSO at 10 mM. Purity is typically ≥95%. Storage at -20degC is recommended. As a natural product ginsenoside, it has limited oral bioavailability and is typically used in research settings.
|
| Toxicity/Toxicokinetics |
Toxicological data for Ginsenoside Rg6 are not well characterized. As a natural product, standard safety precautions should be observed. The compound is for laboratory use only and not intended for human therapeutic applications. Ginsenosides as a class are generally considered to have favorable safety profiles. Comprehensive toxicity profiling would be required for therapeutic development.
|
| References |
|
| Additional Infomation |
Ginsenoside Rg6 is a triterpenoid compound. It has been reported that ginseng contains ginsenoside Rg6, and relevant data are available for reference.
Ginsenoside Rg6 (CAS# 147419-93-0) is a natural compound extracted from steamed notoginseng. It inhibits NF-kappaB transcriptional activity (IC₅0 = 25.12-29.34 microM) and induces apoptosis through mitochondrial dysfunction. The compound is used in research for neuroprotection, inflammation, and metabolic regulation and is not approved for clinical use. |
| Molecular Formula |
C42H70O12
|
|---|---|
| Molecular Weight |
766.9980
|
| Exact Mass |
766.486
|
| CAS # |
147419-93-0
|
| PubChem CID |
91895489
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
850.6±65.0 °C at 760 mmHg
|
| Flash Point |
468.2±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.589
|
| LogP |
8.2
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
54
|
| Complexity |
1380
|
| Defined Atom Stereocenter Count |
20
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2O[C@H]3C[C@@]4([C@H](C[C@H]([C@H]5[C@]4(CC[C@@H]5C(=C)CCC=C(C)C)C)O)[C@@]6([C@@H]3C([C@H](CC6)O)(C)C)C)C)CO)O)O)O)O)O
|
| InChi Key |
ZVTVWDXRNMHGNY-JOGTXEPTSA-N
|
| InChi Code |
InChI=1S/C42H70O12/c1-20(2)11-10-12-21(3)23-13-16-41(8)29(23)24(44)17-27-40(7)15-14-28(45)39(5,6)36(40)25(18-42(27,41)9)52-38-35(33(49)31(47)26(19-43)53-38)54-37-34(50)32(48)30(46)22(4)51-37/h11,22-38,43-50H,3,10,12-19H2,1-2,4-9H3/t22-,23+,24+,25-,26+,27+,28-,29-,30-,31+,32+,33-,34+,35+,36-,37-,38+,40+,41+,42+/m0/s1
|
| Chemical Name |
(2S,3R,4R,5R,6S)-2-[(2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-(6-methylhepta-1,5-dien-2-yl)-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-methyloxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~130.38 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.26 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.26 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.26 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3038 mL | 6.5189 mL | 13.0378 mL | |
| 5 mM | 0.2608 mL | 1.3038 mL | 2.6076 mL | |
| 10 mM | 0.1304 mL | 0.6519 mL | 1.3038 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
